FIELD: biotechnology.
SUBSTANCE: disclosed are antibody molecules which bind to CD137 and OX40 and are capable of having an agonist effect on both CD137 and OX40. Said antibody molecules contain a CDR-based binding site for CD137 and an antigen-binding site for OX40, which is located in the constant domain of the antibody molecule. Also disclosed is a pharmaceutical composition containing said antibodies. Invention also relates to nucleic acids coding antibodies, expression vectors and host cells containing said nucleic acids, a method of producing the antibody.
EFFECT: invention provides highly effective activation of immune cells with reduced risk of toxicity and can be used in treating cancer.
25 cl, 15 dwg, 39 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
